Characterise the immune milieu of pancreatic cancer and to derive optimal combinations of radiotherapy with immunotherapy and/or DNA Damage Response (DDR) inhibitors

As part of the Experimental Medicine Training Initiative applications are invited for a prestigious fully-funded, 3 year Clinical Research Associate position, encompassing a PhD Studentship at the University of Cambridge.

This innovative initiative is a partnership between the University of Cambridge, Cambridge Biomedical Research Centre and major pharmaceutical companies. The Studentship is available from 1st October 2018 and provides an unrivalled opportunity to undertake high quality clinical research in the area of Oncology/tumour immunology/radiotherapy in collaboration with AstraZeneca/Medimmune. It will appeal to Clinical/Radiation Oncologists, either in training or about to complete specialist training, who would like to pursue a career as an academic Clinical/Radiation Oncologist. The Studentship award will cover a clinical salary for up to 3 years, University and College fees and a generous training allowance.

This project is a unique opportunity to join a collaboration between the Division of Experimental Medicine and Immunotherapeutics at the University of Cambridge, the Cambridge Cancer Centre and Astra Zeneca/ MedImmune. The remit is to characterise the immune milieu of pancreatic cancer and to derive optimal combinations of radiotherapy with immunotherapy and/or DNA Damage Response (DDR) inhibitors, through window of opportunity feasibility studies in operable pancreatic cancer. A preclinical (co-clinical) study will explore various combinations of novel agents with radiotherapy in genetically engineered mouse models of pancreatic cancer. This project will provide the successful applicant with an opportunity to apply their strengths to Oncology and experimental medicine, and a unique hands-on perspective of translational medicine.